Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiency

Kidney International

Volumn 72, Issue 1, 2007, Pages 72-81

  Brown, N J ^a   Bradford, J ^a   Wang, Z ^a   Lea, W ^a   Ma, L ^a   Ma, J ^a   Vaughan, D E ^a   Fogo, A B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Angiotensin; Norepinephrine; Plasminogen activator inhibitor 1

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 1A RECEPTOR; ANGIOTENSIN 1B RECEPTOR; ANGIOTENSIN II; LOSARTAN; MESSENGER RNA; NORADRENALIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEART; KIDNEY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR GENE; SYSTOLIC BLOOD PRESSURE; TISSUE SPECIFICITY; WILD TYPE;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; BLOOD PRESSURE; GENE EXPRESSION REGULATION; KIDNEY; LIVER; LOSARTAN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; NOREPINEPHRINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RANDOM ALLOCATION; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER; VASOCONSTRICTOR AGENTS;

EID: 34347334552     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002268     Document Type: Article

References (44)

1. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995; 95: 995-1001.
2. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995; 95: 1353-1362.
3. Saksela O, Rifkin DB. Cell-associated plasminogen activation:regulation and physiologic functions. Annu Rev Cell Biol 1988; 4: 93-126.
4. Eren M, Painter CA, Atkinson JB et al. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002; 106: 491-496.
5. Thogersen AM, Jansson JH, Boman K et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-2247.
6. Collet JP, Montalescot G, Vicaut E et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 2003; 108: 391-394.
7. Eitzman DT, McCoy RD, Zheng X et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97: 232-237.
8. Kaikita K, Fogo AB, Ma L-J et al. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to chronic nitric oxide synthase inhibition. Circulation 2001; 104: 839-844.
9. Huang Y, Haraguchi M, Lawrence DA et al. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 2003; 112: 379-388.
10. Ingelfinger JR. Forestalling fibrosis. N Engl J Med 2003; 349: 2265-2266.
11. Oda T, Jung YO, Kim HS et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 2001; 60: 587-596.
12. Ma J, Weisberg A, Griffin JP et al. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 2006; 69: 1064-1072.
13. Rydzewski B, Zelezna B, Tang W et al. Angiotensin II stimulation of plasminogen activator inhibitor-1 gene expression in astroglial cells from the brain. Endocrinology 1992; 130: 1255-1262.
14. Gesualdo L, Ranieri E, Monno R et al. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney Int 1999; 56: 461-470.
15. Skurk T, Lee YM, Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 2001; 37: 1336-1340.
16. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96: 2515-2520.
17. Mehta JL, Li DY, Yang H, Raizada MK. Angiotensin II and IV stimulate expression and release of plasminogen activator inhibitor-1 in cultured human coronary artery endothelial cells. J Cardiovasc Pharmacol 2002; 39: 789-794.
18. Nakamura S, Nakamura I, Ma L et al. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000; 58: 251-259.
19. Chen HC, Bouchie JL, Perez AS et al. Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-1 gene expression. Arterioscler Thromb Vasc Biol 2000; 20: 2297-2302.
20. Abrahamsen CT, Pullen MA, Schnackenberg CG et al. Effects of angiotensins II and IV on blood pressure, renal function, and PAI-1 expression in the heart and kidney of the rat. Pharmacology 2002; 66: 26-30.
21. Tsujino T, Naito Y, Kawasaki D et al. Circadian expression of plasminogen activator inhibitor-1 in angiotensin II type 1a receptor knockout mice. Clin Exp Hypertens 2005; 27: 159-168.
22. Chen HC, Bouchie JL, Perez AS et al. Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-1 gene expression. Arterioscler Thromb Vasc Biol 2000; 20: 2297-2302.
23. Papakonstantinou E, Roth M, Kokkas B et al. Losartan inhibits the angiotensin II-induced modifications on fibrinolysis and matrix deposition by primary human vascular smooth muscle cells. J Cardiovasc Pharmacol 2001; 38: 715-728.
24. Esteban V, Ruperez M, Sanchez-Lopez E et al. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells. Circ Res 2005; 96: 965-973.
25. Hoffmann A, Cool DR. Characterization of two polyclonal peptide antibodies that recognize the carboxy terminus of angiotensin II AT1A and AT1B receptors. Clin Exp Pharmacol Physiol 2005; 32: 936-943.
26. Briest W, Homagk L, Rassler B et al. Norepinephrine-induced changes in cardiac transforming growth factor-beta isoform expression pattern of female and male rats. Hypertension 2004; 44: 410-418.
27. Akiyama-Uchida Y, Ashizawa N, Ohtsuru A et al. Norepinephrine enhances fibrosis mediated by TGF-beta in cardiac fibroblasts. Hypertension 2002; 40: 148-154.
28. Noble NA, Border WA. Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target? Semin Nephrol 1997; 17: 455-466.
29. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 2000; 15: 290-301.
30. Brown NJ, Nakamura S, Ma L-J et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58: 1219-1227.
31. Oestreicher EM, Martinez-Vasquez D, Stone JR et al. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. Circulation 2003; 108: 2517-2523.
32. Aldigier JC, Kanjanbuch T, Ma LJ et al. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005; 16: 3306-3314.
33. Naruse M, Tanabe A, Sugaya T et al. Deferential roles of angiotensin receptor subtypes in adrenocortical function in mice. Life Sci 1998; 63: 1593-1598.
34. Katada J, Meguro T, Saito H et al. Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation 2005; 111: 2157-2164.
35. Story DF, Ziogas J. Interaction of angiotensin with noradrenergic neuroeffector transmission. Trends Pharmacol Sci 2003; 8: 269-271.
36. Lu D, Yu K, Paddy MR et al. Regulation of norepinephrine transport system by angiotensin II in neuronal cultures of normotensive and spontaneously hypertensive rat brains. Endocrinology 1996; 137: 763-772.
37. Li HT, Long CS, Gray MO et al. Cross talk between angiotensin AT1 and alpha 1-adrenergic receptors: angiotensin II downregulates alpha 1a-adrenergic receptor subtype mRNA and density in neonatal rat cardiac myocytes. Circ Res 1997; 81: 396-403.
38. Barki-Harrington L, Luttrell LM, Rockman HA. Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation 2003; 108: 1611-1618.
39. Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA. Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril. J Hypertens 2001; 19: 465-473.
40. Dendorfer A, Raasch W, Tempel K, Dominiak P. Comparison of the vascular and antiadrenergic activities of four angiotensin II type 1 antagonists in the pithed rat. J Hypertens 2002; 20: 1151-1156.
41. Raasch W, Dominiak P, Ziegler A, Dendorfer A. Reduction of vascular noradrenaline sensitivity by AT1 antagonists depends on functional sympathetic innervation. Hypertension 2004; 44: 346-351.
42. Brown NJ, Kumar S, Painter CA, Vaughan DE. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension 2002; 40: 859-865.
43. Goodfield NE, Newby DE, Ludlam CA, Flapan AD. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. [see Comments]. Circulation 1999; 99: 2983-2985.
44. Eren M, Painter CA, Gleaves LA et al. Tissue- and agonist-specific regulation of human and murine plasminogen activator inhibitor-1 promoters in transgenic mice. J Thromb Haemost 2003; 1: 2389-2396.